Clinical Trials Logo
  1. Home
  2. Hypertension
  3. NCT04900545
  4. Details
NCT04900545 Clinical Trial

Effect of Genetic Polymorphisms on Response to Beta Blocker Therapy in Egyptian Patients

Hypertension Clinical Trial

Official title:
Effect of Genetic Polymorphisms on Response to Beta Blocker Therapy in Egyptian Patients

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04900545
Other study ID # PHCL135
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 5, 2021
Est. completion date August 1, 2021

Study information
Verified date November 2022
Source Ain Shams University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Beta-blockers represent a cornerstone for the treatment of coronary artery disease (CAD). Their protective effect is based on the negative inotropic and chronotropic features, which have been tested in a large number of randomized controlled trials, both in patients with myocardial infarction (MI) and in those with stable angina, demonstrating a reduction of adverse cardiovascular events, a relief of symptoms and a reduction of myocardial ischemia However, considerable interpatient variability in response to β-blockers has been reported which indicates that a considerable proportion of β-blocker-treated patients do not achieve the warranted cardio protection with β- blockers. This highlights the importance of identifying biomarkers associated with variability in response to β-blockers to improve the current approach for β- blocker selection, which seems to be suboptimal. This study aims to study the effect of polymorphism in adrenergic beta receptors on beta-blocker response in Egyptian patients.

Recruitment information / eligibility
Status Completed
Enrollment 80
Est. completion date August 1, 2021
Est. primary completion date May 25, 2021
Accepts healthy volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Beta-blockers naïve patients 2. Patients been on beta-blocker therapy for at least 4 weeks. 3. Age (18-75) Years old. Exclusion Criteria: 1. Non-Egyptians. 2. Kidney failure of any stage. 3. Liver failure of any stage. 4. Malignancy. 5. Pregnancy. 6. HR < 55 beats/min (in the absence of b-blocker therapy). 7. Presence of a cardiac pacemaker.

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Egypt Ain Shams University Hospitals. Cairo Al Qahirah

Sponsors (1)
Lead Sponsor Collaborator
Mohamed Saleh Fayed

Country where clinical trial is conducted

Egypt, 

Outcome
Type Measure Description Time frame Safety issue
Primary Adrenergic receptors genes and blood pressure response to beta-blocker Investigate the association of the adrenergic receptor polymorphisms with reduction in blood pressure (expressed in units of millimeters of mercury "mmHg" ) in the Egyptian patients with acute coronary syndrome on beta blocker therapy. Three months
Primary Adrenergic receptors genes and heart rate response to beta-blocker Investigate the association of the adrenergic receptor polymorphisms with reduction in heart rate (expressed as beats per minute "BPM" ) in the Egyptian patients with acute coronary syndrome on beta blocker therapy. Three months
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A